Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Vical (NASDAQ:VICL) Share Price
Press coverage about Vical (NASDAQ:VICL) has been trending somewhat positive on Tuesday, according to Accern Sentiment. The research group ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Vical earned a news sentiment score of 0.17 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 46.503992714246 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Here are some of the headlines that may have effected Accern Sentiment Analysis’s analysis:
- Vical Incorporated (NASDAQ:VICL) Stock Rating Reaffirmed by Ifs Securities (americanbankingnews.com)
- Investor Network Invites You to the Vical Second Quarter 2017 Earnings Webcast Live on Tuesday, August 8, 2017 (finance.yahoo.com)
- Edited Transcript of VICL earnings conference call or presentation 8-Aug-17 4:00pm GMT (finance.yahoo.com)
- Vical Incorporated : Investor Network: Vical Incorporated to Host Earnings Call (4-traders.com)
- Vical Incorporated’s (VICL) CEO Vijay Samant on Q2 2017 Results – Earnings Call Transcript (seekingalpha.com)
A number of brokerages recently issued reports on VICL. HC Wainwright set a $9.00 price objective on Vical and gave the company a “buy” rating in a research note on Wednesday, August 9th. Ifs Securities restated an “outperform” rating on shares of Vical in a research note on Tuesday, August 8th. Finally, Rodman & Renshaw restated a “buy” rating and issued a $9.00 price objective on shares of Vical in a research note on Monday, June 12th.
Shares of Vical (NASDAQ:VICL) opened at 2.47 on Tuesday. The company’s market capitalization is $27.41 million. The stock’s 50 day moving average price is $2.61 and its 200 day moving average price is $2.35. Vical has a 12 month low of $2.05 and a 12 month high of $4.45.
Vical (NASDAQ:VICL) last announced its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by $0.02. The firm had revenue of $3.42 million during the quarter, compared to analysts’ expectations of $3.35 million. Vical had a negative return on equity of 26.09% and a negative net margin of 92.02%. On average, analysts forecast that Vical will post ($1.05) EPS for the current year.
Vical Company Profile
Receive News & Ratings for Vical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vical Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.